3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
40
Carcinoma, Non-Small-Cell Lung
32
Colorectal Neoplasms
27
Ovarian Neoplasms
23
Neoplasms
23
Lung Neoplasms
20
Precursor Cell Lymphoblastic Leukemia-Lymphoma
18
Pancreatic Neoplasms
17
Leukemia, Myeloid, Acute
16
Head and Neck Neoplasms
16
Lymphoma, Non-Hodgkin
15
Neoplasm Metastasis
14
Fallopian Tube Neoplasms
14
Glioblastoma
13
Esophageal Neoplasms
12
Rectal Neoplasms
11
Lymphoma
11
Squamous Cell Carcinoma of Head and Neck
10
Central Nervous System Neoplasms
10
Carcinoma, Ovarian Epithelial
10
Recurrence
9
Melanoma
9
Lymphoma, Large B-Cell, Diffuse
9
Lymphoma, Follicular
9
Leukemia
9
Stomach Neoplasms
8
Prostatic Neoplasms
8
Lymphoma, Mantle-Cell
7
Lymphoma, B-Cell, Marginal Zone
7
Liver Neoplasms
7
Interventions
Cisplatin
8
Ifosfamide
7
Etoposide
7
Paclitaxel
6
Filgrastim
6
Bleomycin
6
Carboplatin
5
Peripheral Blood Stem Cell Transplantation
3
pegfilgrastim
2
liposomal amphotericin B
2
Therapeutics
2
Radiotherapy
2
Granulocyte Colony-Stimulating Factor
2
Cyclophosphamide
2
sargramostim
1
sabarubicin
1
ixabepilone
1
etoposide phosphate
1
aldesleukin
1
Vincristine
1
Thiotepa
1
Taxes
1
Surgical Procedures, Operative
1
Sunitinib
1
Ribavirin
1
Psychiatric Rehabilitation
1
Palivizumab
1
Oxaliplatin
1
Mesna
1
Magnetic Resonance Spectroscopy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Endodermal Sinus Tumor
×
Drug Therapy
×
Clear all
NCT06341998
2025-09-19
SCRRYST
Shandong First Medical University
Phase 2/3
Completed
32 enrolled